Christophe Demaison

The University of Melbourne, founded in 1853, is a world-renowned institution located in Parkville, Australia. The university is a leader in education, teaching, and research, offering a wide range of coursework and research programs.

Monash University operates as a public research university. It specializes in higher education, global engagement, postgraduate courses, undergraduate study, and PhD research. The company was founded on March 1961 and is headquartered in Clayton, Australia.

Hatchtech Pty Ltd. operates as pharmaceutical product company. It offers Xeglyze lotion that is head lice treatment. The company was founded by Vernon Morrison Bowles in 2001 and is headquartered in in Melbourne, Australia.

Fibrotech Therapeutics Pty Ltd develops novel drug candidates for the treatment of the fibrosis prevalent in such chronic conditions as kidney disease, chronic heart failure, pulmonary fibrosis, and arthritis. The company was founded by Richard Ernest Gilbert, Darren James Kelly, Spencer J Williams, Steven C Zammit, David Stapleton, Henry Krum and Yuan Zhang in 2006 and is headquartered in Melbourne, Australia.

Otifex Therapeutics Pty Ltd. develops treatment for ear diseases. The company was founded by Burkhard Franz and Colin Anderson in 2009 and is headquartered in Melbourne, Australia.

OccuRx Pty Ltd provides biopharmaceutical services. It engages in the development of therapeutic strategies for the treatment of ophthalmic disorders associated with retinal fibrosis and inflammation. The company was founded by Darren J. Kelly in 2014 and is headquartered in Melbourne, Australia.

Uniseed Management Pty Ltd. (Uniseed) is an independent Australian venture capital firm which was founded in 2000. The firm headquartered in Australia.

Australian Investment Council is an Australian private company located in Sydney. The firm operates as an association. Navleen Prasad has been the CEO since 2022.

Certa Therapeutics Pty Ltd. operates as biotechnology company. The firm develops drugs for treatment for kidney disease. The company was founded by Darren James Kelly and is headquartered in Melbourne, Australia.

Cortical Pty Ltd. discovers and develops medical drugs for the treatment of inflammatory and proliferative diseases. The company was founded in 2003 by Eric F. Morand and Magdy N. Iskander and is headquartered in Clayton, Australia.

Australian Institute of Co. Directors is a non-profit organization that provides leadership on director issues. It offers governance education, director development, and advocacy. The organization was founded in January 1, 1990 and is headquartered in Sydney, Australia.

d3 Medicine LLC develops drugs and medicines. It is strategic advisory company focused on developing medicines for use in indications including infectious diseases, oncology, and inflammation. The company was founded by Craig Rayner in 2012 and is headquartered in Parsippany, NJ.

Certara USA, Inc. provides drug development consultancy solutions. It offers benefits of modeling and simulation, label optimization, pediatric drug development, orphan drug development, clinical trial outcomes databases, and therapeutic areas. The company was founded in 2008 and is headquartered in Princeton, NJ.

GBS Venture Partners Pty Ltd (GBS Venture Partners) is a venture capital firm founded in 1996 by Helen Brigitte Smith and Geoff E.D Brooke. The firm is headquartered in Melbourne.

Pathios Therapeutics Ltd. engages in discovering and developing novel small molecule drugs. The company was founded by Thomas David McCarthy, Alan Naylor, Kirsty McCarthy, Peter Joyce and Someit Sidhu in 2017 and is headquartered in Oxford, the United Kingdom.

Medical Research Commercialisation Fund Trust invests in life science companies located in Australia. The fund focuses on companies operating in the fields of medical research institutes and allied research hospitals. It provides seed and early stage financing in project investment of up to $0.02 million, at the stage of company formation invests up to $4 million and also makes follow-on investments of up to $2 million. It seeks co-investment with other investors for technologies with larger capital requirements.

Azura Ophthalmics Ltd. develops therapies for meibomian gland dysfunction. It offers a portfolio of compounds in combination with a novel drug delivery platform to advance a portfolio of treatments for meibomian gland dysfunction. The company was founded by Yair Alster in 1980 and is headquartered in Tel Aviv, Israel.

QUE Oncology, Inc. engages in preventing and treating life-threatening cancers such as prostate cancer, breast cancer, melanoma, and cancer pain; and related conditions. The company is headquartered in Atlanta, GA.

PolyActiva Pty Ltd. develops drug-polymer conjugate technology. Its platform technology is used to make plastic components for medical devices from drugs and manufacture process is novel and provides greater flexibility over the composition of the final material and better product outcomes compared with competitor technologies. The firm has built drug-polymer conjugates from a number of drug candidates with different chemical structures and linkage points, demonstrating the plasticity of the technology and developed a number of functional co-monomers and polymer segments, which modularises the production of the final conjugate. The company was founded in February 2010 and is headquartered in Melbourne, Australia.

Nexgen Plants Pty Ltd. develops anti-viral technology solutions that enables virus resistant plant varieties to be developed for major food, fibre, energy and ornamental crops. The company was founded in 2013 and is headquartered in St. Lucia, Australia.

Exonate engages in the discovery and development of small molecule drugs that modulate alternative mRNA splicing to address diseases of high unmet medical need. It develops SPHINXes, a pipeline of novel small molecule inhibitors. The company was founded by David Owen Bates, Lucy Donaldson, Steeven J. harper and Catherine Beech in 2013 and is headquartered in Nottingham, the United Kingdom.

Brandon Capital Partners Pty Ltd. (Brandon Capital Partners) is a venture capital firm founded in 2007 by David Fisher and Chris Nave. The firm is headquartered in Sydney, Australia.

Global Kinetics Pty Ltd. provides point of care measurement and reporting of Parkinson's disease motor symptoms. Its product includes Personal KinetiGraph (PKG), a wrist worn medical device which reminds the patient when they have taken Levodopa medication as prescribed by doctor. The company was founded by Robert Griffiths and Malcolm Horne in 2007 and is headquartered in Melbourne, Australia.

AusBiotech Ltd. operates as an Australian biotechnology membership company. The private company is based in Melbourne, Australia. and has subsidiaries in Australia. The company was founded by Liz Dallimore. Lorraine Chiroiu has been the CEO of the company since 2008.

Baker Heart & Diabetes Institute owns and operates a medical research institute. The company is headquartered in Melbourne, Australia.

Cardiora Pty Ltd. functions as a clinical stage pharmaceutical company. It develops CRD-102, an oral medicine for heart failure. The company was founded by David Kaye in 2015 and is headquartered in Melbourne, Australia.

Solvanix Pty Ltd. develops novel therapy for improving stability and reducing the aggregation of fully human antibodies. The company was founded by Daniel Christ in 2014 and is headquartered in Darlinghurst, Australia.